New Market Report: Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022

From: Fast Market Research, Inc.
Published: Mon Jun 10 2013


GlobalData has released its new PharmaPoint Drug Evaluation report, "Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022". Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients' survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.

Full Report Details at
- http://www.fastmr.com/prod/608212_tasigna_chronic_myeloid_leukemia_forecast_and.aspx?afid=303

Novartis' Tasigna (nilotinib) is a second-generation BCR-ABL TKI. It was first approved in the US and 5EU in 2007 and in Japan in 2009 as a second-line therapy for patients with CP or AP CML that was intolerant or resistant to Gleevec. Shortly thereafter, in 2010, Tasigna gained regulatory approval for the first-line treatment of CP-CML patients in the US and the EU. In Japan, Tasigna received this brand extension in 2011. It is approved and reimbursed for both indications in all the 7MM. Tasigna has orphan drug designation from both the FDA and the EMA. Tasigna is administered twice daily at a dose of 300mg for newly diagnosed CP CML or 400mg when used as a second-line therapy, and must be taken on an empty stomach.

Scope

* Overview of CML, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Tasigna including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Tasigna for the top seven countries from 2012 to 2022.
* Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for CML
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Tasigna performance
* Obtain sales forecast for Tasigna from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022
- PharmaPoint: Chronic Myeloid Leukemia (CML) - Italy Drug Forecast and Market Analysis to 2022
- PharmaPoint: Chronic Myeloid Leukemia (CML) - France Drug Forecast and Market Analysis to 2022
- PharmaPoint: Chronic Myeloid Leukemia (CML) - Japan Drug Forecast and Market Analysis to 2022
- PharmaPoint: Chronic Myeloid Leukemia (CML) - Spain Drug Forecast and Market Analysis to 2022
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »